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Abstract
Background: Cervical cancer is the most common malignant gynecological cancer, and lymphatic
metastasis can occur in the early stage of tumor growth. Lymphatic vessel endothelial hyaluronan
receptor-1 (LYVE-1), a marker for lymphatic endothelium, provides powerful tools for studying
tumor lymphangiogenesis. The purpose of this study is to investigate the clinical implications of
lymphangiogenesis in the metastasis of early-stage invasive cervical carcinoma.
Methods: We used immunohistochemical (IHC) staining with the antibody against LYVE-1 to
measure lymph vessel density in 41 cases of early-stage invasive cervical carcinoma and 12 cases of
normal cervical samples. We then analyzed the correlation between lymph vessel density and
clinicopathological features of the tumors.
Results: (1) The majority of peritumoral lymphatics were enlarged, dilated, and irregular. In
contrast, intratumoral lymph vessels were small and collapsed. The peritumoral lymphatic vessel
density (PLVD) was significantly higher than the intratumoral lymphatic vessel density (ILVD) (P <
0.01). (2) Both ILVD and PLVD were significantly higher than the LVD of the control cervixes (P <
0.01). (3) Both ILVD and PLVD were significantly associated with lymph node metastasis (ILVD, P
< 0.05; PLVD, P < 0.01) and lymphatic vessel invasion (ILVD, P < 0.05; PLVD, P < 0.01). Both the
ILVD and PLVD in patients with histological grade HG2 and HG3 were significantly higher than
those with HG1 (P < 0.05).
Conclusion: Tumor lymphangiogenesis in early-stage invasive cervical carcinoma may play an
important role in the process of lymphatic metastasis.
Background
The bloodstream and lymph system are two common
pathways by which tumor cells spread. A significant
amount of laboratory and clinical research indicates that
tumor angiogenesis plays important roles in tumor
growth and metastasis. On the other hand, research on
tumor lymphangiogenesis lags behind, mostly because of
the lack of specific markers of lymphatic endothelium.
Recently, several markers for lymphatic endothelium have
been discovered, including transmembrane protein lym-
phatic vessel endothelial hyaluronan receptor-1 (LYVE-1),
and these provide powerful tools for studying tumor lym-
phangiogenesis.
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logical cancer, and lymphatic metastasis can occur in the
early stage of tumor growth. The role of tumor lymphang-
iogenesis in metastasis of early-stage cervical carcinoma is
gradually becoming the focus of research. In this study,
the role of lymphangiogenesis in cervical cancer metasta-
sis was investigated using clinical patient samples[1].
Methods
Patients and tissue samples
Patients (n = 41) with cervical carcinoma who were
treated between September 2007 and June 2008 were
enrolled in the study. The tissue samples were obtained at
the time of surgery in the Department of Gynecology,
Qilu Hospital, Shandong University. The present study
was approved by the ethics committee of the Shandong
University. All samples were obtained with medical-ethics
approval and all patients gave informed consent. Tissues
were fixed with 4% paraformaldehyde and paraffin-
embedded for further analysis. The pathological examina-
tion validated the fact that no radio- or chemotherapy was
received before surgery. All patients with early-stage inva-
sive cervical cancer were staged according to the 2000
International Federation of Gynecology and Obstetrics
(FIGO) staging system. Seven patients had a cervical can-
cer classified as FIGO stage Ia, 14 as FIGO stage Ib, and 20
as FIGO stage IIa. Based on analysis of cellular differenti-
ation, seven cases were HG1, 13 were HG2, and 21 were
HG3. Of all the cases, 37 were squamous cell carcinomas
and four were adeno-carcinomas. Histological review con-
firmed that 15 cases showed lymph node metastasis.
Lymph node status was determined by routine pathologi-
cal examination with the surgical specimens. The standard
for lymphatic vessel invasion was the detection of cancer
cells in the cavity of the lymphatic vessel by light micros-
copy. By this standard, 35 cases showed lymphatic vessel
invasion and six were negative. The age of the patients var-
ied from 26 to 70, with a median value of 42. Of all the
patients, 29 were premenopausal and 16 were postmeno-
pausal. Pelvic/paraaortic lymph node dissection was per-
formed in all cases; the mean and median number of
lymph nodes per case examined was 24.7 and 24.0,
respectively (range 1–82). Lymph node status was deter-
mined by routine pathological examination with the sur-
gical specimens. Lymph node metastasis was present in 15
(36.6%) cases; the mean and median number of positive
lymph nodes was 2.5 and 2.0, respectively (range 1–7).
All tissue specimens and slides were examined by experi-
enced pathologists.
Immunohistochemistry
Immunohistochemistry (IHC) was done using the immu-
nohistochemistry SP kit from Jingmei Inc. (Shanghai,
China; catalog no. LHK612) according to the manufac-
turer's instructions. Briefly, serial section slides of 5 μm
were obtained from the paraffin-embedded specimens
and the paraffin medium was removed. The slides were
then re-hydrated by passing through a descending serial
alcohol dilutions. Then the slides were placed in antigen
retrieval solution (pH 6.0) and heated in a microwave
oven for 10 min at 95°C. Next, the slides were incubated
in a 3% hydrogen peroxide-methanol solution for 10 min
to remove endogenous peroxidase. IHC staining was per-
formed as follows: nonspecific binding was blocked with
10% goat serum; the slide was incubated for 1 h with pol-
yclonal rabbit anti-LYVE-1 antibody (1:80 dilution,
Abcam, catalog # ab36993), followed by incubation for
10 min with biotin-labeled secondary antibody; then the
slide was incubated for 10 min with horseradish peroxi-
dase-labeled streptavidin. Color was developed using
DAB, and the slide was counterstained with hematoxylin.
Finally, the slides were mounted and coverslipped with
resinene. Negative control slides were stained with PBS
instead of LYVE-1 antibody.
Intratumoral and peritumoral lymphatic vessel density
(LVD) was determined according to the methods previ-
ously described by Weidner et al.[2] and Gombos et al.[3].
Briefly, the following had to be observed in order for lym-
phatic vessels to be considered positively stained: (1)
brown-yellow stained endothelial cells forming tubular
structures and situated on their own or bundled, and (2)
an open cavity inside the tubular structure. The slides were
scanned on a low-power microscope and intra- and peri-
tumoral areas with the highest vessel density, called hot
spots, were identified. The number of lymphatic vessels in
five high-power fields in the selected areas was counted.
LVD was determined as the mean value of vessel counts.
Intratumoral lymphatic vessels were defined as those
located within the tumor mass. Peritumoral lymphatic
vessels were those located outside of the tumor mass, but
within 2 mm from the tumor. The lymphatic vessels in the
control samples were defined as those located in the stro-
mal area, within 2 mm of the underlying basement mem-
branes. The slides were evaluated independently by
investigators blinded to the clinical data.
Statistical Analysis
All statistical calculations were performed using SPSS (ver-
sion 13.0, Chicago, IL USA). LVDs are expressed as mean
± SD. The statistical methods used include the t-test, one-
way ANOVA test, and the Kruskal-Wallis test. Differences
were considered statistically significant when P < 0.05.
Results
Morphology of lymphatic vessels in cervical cancer tissue
Lymphatic vessels in the control uterine cervix are often
open and have a regular shape (Figure 1A). Under the
high-power light microscope, the positively stained ves-Page 2 of 6
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vessel endothelium was usually a single layer of cells, each
with a large nucleus extruding toward the lumen face (Fig-
ure 1B). In contrast, most of the lymphatic vessels in cer-
vical carcinoma tissue were localized around the tumor
mass in increased numbers. They were often in irregular
shape with an enlarged cavity. The lymphatic vessels in
the tumor mass were small, collapsed tubular structures
that were either isolated or bundled (Figure 1C). At the
same time, invasive cancer cells were observed in some
peritumoral lymphatic vessels (Figure 1D).
Lymphatic vessel density
The intratumoral lymphatic vessel density (ILVD) was
7.71 ± 1.12 and peritumoral lymphatic vessel density
(PLVD) was 9.10 ± 0.80. PLVD was significantly higher
than ILVD (P < 0.01) in the corresponding cervical carci-
noma samples. The ILVD and PLVD associated with carci-
nomas in situ were both significantly higher than the LVD
of the normal uterine cervix (2.08 ± 1.00) (P < 0.01).
The clinicopathological features and LVD data are sum-
marized in Table 1. In samples from patients with lymph
node metastasis, the ILVD was 8.27 ± 0.80 and the PLVD
Morphology of lymphatic vessels in cervical cancer tissueFigure 1
Morphology of lymphatic vessels in cervical cancer tissue. (A) The lymph vessels of the normal cervix control were 
open and regular (arrow). Primary antibody: LYVE-1 polyclonal antibody, magnification: ×200. (B) Blood vessel endothelial 
cells, negative by immunostaining, with some red blood cells in the capillary lumen (arrow). Primary antibody: LYVE-1 polyclo-
nal antibody, magnification: ×400. (C) The intratumoral lymph vessels were small and collapsed (←); in contrast, the peritu-
moral lymphatics were often dilated, and irregularly shaped (→). Primary antibody: LYVE-1 polyclonal antibody, magnification: 
×200. (D) Some invading cancer cells were present in lymph vessels (star). Primary antibody: LYVE-1 polyclonal antibody, mag-
nification: ×400.Page 3 of 6
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higher than the corresponding values in the samples with-
out metastasis (7.38 ± 1.17, 8.77 ± 0.65, respectively; P <
0.05, P < 0.01). Similarly, ILVD and PLVD were found to
correlate significantly with lymphatic vessel invasion (P <
0.05 and P < 0.01, respectively). The ILVD and PLVD from
cases showing lymphatic vessel invasion were much
higher than in those cases without invasion although
these differences did not reach statistical significance
(8.67 ± 0.82 vs. 7.54 ± 1.09, 9.67 ± 0.72 vs. 8.94 ± 0.73).
Meanwhile, we also analyzed the correlation between the
histological grade and the ILVD or PLVD. The ILVDs for
cases of HG1, HG2, and HG3 were 6.57 ± 0.96, 7.85 ±
1.14, and 8.00 ± 0.95, respectively. The PLVDs for cases of
HG1, HG2, and HG3 were 8.29 ± 0.76, 9.31 ± 0.63, and
9.24 ± 0.77, respectively. The ILVDs and PLVDs for HG2
and HG3 cases were significantly higher than the corre-
sponding values for HG1 cases (P < 0.05). There was no
significant difference between the HG2 and HG3 cases.
On the other hand, LVDs showed no correlation with
patient clinical stages, menopause condition, or carci-
noma histology. The depth of tumor invasion, an impor-
tant clinicopathological feature, was not correlation with
depth of tumor invasion and the lymph vessel density.
Discussion
The lymphatic system is involved in multiple physiologi-
cal processes, such as maintenance of the internal envi-
ronment and immune surveillance. It also plays
important roles in different kinds of pathological proc-
esses, including lymphatic swelling, tissue repair, inflam-
mation, and especially tumor metastasis[4]. The last
process is a major risk factor for tumor prognosis. Cervical
cancer metastasizes mostly by direct spreading and lym-
phatic invasion, but rarely by traveling through the blood-
stream. Therefore, studying lymphangiogenesis has
important implications for understanding lymphatic
metastasis of cervical cancer. Currently, the available
endothelial markers for lymphatic vessels include vascular
endothelial growth factor receptor-3 (VEGFR-3), LYVE-1,
Podoplanin, Prox1, and others. LYVE-1 is the homologue
of CD44, and its main physiological functions include
serving as a receptor for hyaluronic acid (HA) and facili-
tating the transport and metabolism of HA in the extracel-
lular matrix. It has also been shown that LYVE-1 is
Table 1: Association of LVD and other clinical and pathological parameters. P, t-test; P*, one-way ANOVA test; P**, Kruskal-Wallis 
test.
ILVD PLVD
Variables N mean ± SD P mean ± SD P
Catamenia
Premenopause 29 7.83 ± 1.10 0.292 9.17 ± 0.80 0.358
Postmenopause 12 7.42 ± 1.12 8.92 ± 0.79
Tumor size (cm)
≤ 4 26 7.58 ± 1.06 0.528 9.08 ± 0.84 0.831
> 4 15 7.93 ± 1.22 9.13 ± 0.74
Stromal invasion
≤ 2/3 17 7.35 ± 0.86 0.089 8.94 ± 0.75 0.298
> 2/3 24 7.96 ± 1.23 9.21 ± 0.83
FIGO stage
Ia 7 6.86 ± 1.07 0.075* 8.57 ± 0.79 0.113*
Ib 14 8.00 ± 1.24 9.07 ± 0.62
IIa 20 7.80 ± 0.21 9.30 ± 0.86
Histological grade
HG1 7 6.57 ± 0.96 0.009* 8.29 ± 0.76 0.012**
HG2 13 7.85 ± 1.14 9.31 ± 0.63
HG3 21 8.00 ± 0.95 9.24 ± 0.77
Lymph node metastasis
Negative 26 7.38 ± 1.17 0.013 8.77 ± 0.65 0.0002
Positive 15 8.27 ± 0.80 9.67 ± 0.72
LVI
Negative 35 7.54 ± 1.09 0.021 8.94 ± 0.73 0.001
Positive 6 8.67 ± 0.82 10.00 ± 0.63
Histological cell type
SCC 37 7.62 ± 1.14 0.139 9.14 ± 0.79 0.367
ADE 4 8.50 ± 0.58 8.75 ± 0.96
Abbreviation: HG, histological grade; LVI, lymphatic vessel invasion; SCC, squamous cell carcinoma; ADE, adenocarcinoma.Page 4 of 6
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uted evenly on the basal and luminal surfaces of lym-
phatic vessels and is considered to be the most useful
marker for lymphatic endothelium[6].
In the current study, we used a polyclonal LYVE-1 anti-
body to label lymphatic vessels. We found that positively
stained lymphatic vessels had an enlarged lumen lacking
red blood cells. Some invasive cancer cells were observed
inside the lumen. Their walls were often irregular and
built up of a single layer of endothelial cells, each with a
large, extruding nucleus. In contrast, the walls of blood
vessels were thick, regular, and consisted of endothelial
cells with flattened nuclei. The lymphatic vessels were eas-
ily distinguished from blood vessels, because the latter
always contained a large amount of red blood cells. In
addition, we found lymphatic vessels in cervical cancers to
differ morphologically from lymphatic vessels in a nor-
mal cervix. The lymphatic vessels in the control cases were
open and regular. The corresponding vessels in cancer
specimens, however, were more numerous and unevenly
distributed, showing a higher density in the peritumoral
area. The morphology of peritumoral lymphatic vessels
was usually dilated and irregular, while the lymphatic ves-
sels in tumor masses were often closed and flattened.
These results are consistent with previous studies[7]. A
possible explanation for this finding is that the tumor
mass increases so quickly, due to rapid cell proliferation,
that the newly developed lymphatic vessels are under high
stromal hydrostatic pressure. Tumor cell invasion may
also impair the integrity of lymphatic vessels[8].
The idea that tumors induce growth of new lymphatic ves-
sels has been controversial. Recently, there have been sig-
nificant improvements in lymphatic endothelial cell
growth factors, markers, and isolation techniques. Using
these new techniques, a large number of animal and clin-
ical studies have confirmed the existence of a newly devel-
oped lymphatic network in the body of a tumor. In
animal tumor models with high-expression levels of lym-
phatic vessel growth factor VEGF-C[9] or VEGF-D[10], the
endothelial cells along lymphatic vessels show prolifera-
tion and a positive stain for proliferating cell nuclear anti-
gen (PCNA). The ILVD and PLVD in these tumors are also
higher than those in normal tissues. In our study, we
found that the ILVD and PLVD of cervical carcinomas are
significantly higher than those of normal cervix tissues.
This is consistent with other clinical studies[11,12].
Under the regulation of lymphatic vessel growth factors,
lymphatic endothelial cells undergo proliferation and
migration to form new vessel cavities. The newly devel-
oped tumor lymphatic vessels have a structure similar to
that of lymphatic vessels under normal physiological con-
ditions, but they are more numerous and they have thin,
leaky walls. These features facilitate the metastasis of
tumor cells.
Thus far, most studies suggest that the lymphatic network
in the peritumoral area may play an important role in
tumor metastasis[13]. Padera et al. performed a dye
absorption experiment and showed that most of the func-
tional lymphatic vessels in tumors are located around the
tumor mass and are positive for PCNA expression[14].
There is some debate about whether the new lymphatic
vessels in the tumor body are functional. Clinical research
has revealed that although the lymphatic vessels in the
tumor mass are PCNA-positive, they may not be func-
tional since they usually consist of a low number of small
and flattened endothelial cells. However, studies using
animal models featuring a high level of lymphatic growth
factors show that new lymphatic vessels strongly correlate
with lymph node metastasis of tumor cells[15]. Therefore,
the newly growing lymphatic vessels have been hypothe-
sized to lie within the tumor mass. As the tumor cells pro-
liferate, the stromal hydrostatic pressure increases rapidly
and leads to the blockage of intratumoral lymphatic ves-
sels. Consistent with Gombos et al.[3], we have shown
here that the ILVD and PLVD strongly correlate with
lymph node metastasis and lymphatic vessel invasion. In
summary, both peri- and intratumoral lymphatic vessels
are involved in lymphatic invasion and metastasis of
tumor cells. Intratumoral lymphatic vessels may function
to provide a direct pathway for the tumor cell to metasta-
size to the lymph nodes in the early stage of tumor
growth, when the stromal hydrostatic pressure is not high
enough to block them. Another possible mechanism is
the more numerous and dilated peritumoral lymphatic
vessels may serve as the metastasis pathway. During this
process, LYVE-1 molecules may provide adhesive force for
tumor cells and further promote tumor lymphatic inva-
sion and lymph node metastasis.
We found that the ILVD and PLVD correlate with histolog-
ical grade. The ILVD and PLVD of medium-low differenti-
ated specimens were significantly higher than those of the
highly differentiated samples. The reason for this may be
that the medium-low differentiated tumor cells are more
malignant and can secrete more growth factors that
induce lymphatic vessel formation and lymph node
metastasis. In addition, we also showed that ILVD and
PLVD do not correlate with patient clinical staging, men-
opause state, or histological type.
Conclusion
The LVD of early-stage cervical carcinoma is significantly
higher than that of a normal cervix, and it strongly corre-
lates with multiple clinicopathological features, such as
lymph node metastasis, lymph vessel invasion, and histo-
logical grade. Therefore, lymphangiogenesis may play anPage 5 of 6
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stage cervical carcinoma.
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